Thông tin tài liệu
TÀI LIỆU THAM KHẢO Corcos J, Schick E (2008), Simplified anatomy of the vesico–urethral functional unit Textbook of neurogenic Bladder; UK, Informa Healthcare: 2: 13-18 Harrington A, Bhandary A (2011), Neurogenic Detrusor Overactivity After Spinal Cord Injury University of Pittsburgh School of Medicine Rehab Grand Rounds: 1-8 Dahlberg A, Perttila I, Wuokko E et al (2004), Bladder management in persons with spinal cord lesion Spinal Cord 42: 694-698 Giannantoni A, Mearini E, Zingaro MD et al (2009), Six-Year FollowUp of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity : Clinical and Urodynamic Results European urology; 55: 705–712 Ku JH (2006), The management of neurogenic bladder and quality of life in spinal cord injury; Journal compilation BJU International; 98:739–745 Shin JC, Chang WH, Jung TH et al (2008), The determination of sensation-dependent bladder emptying time in patients with complete spinal cord injury above T11 Spinal Cord; 46: 210–215 Giannantoni A, Mearini E, Del Zingaro M et al (2008), Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application BJU Iternational; 102, supplement 1, 2–6 Lee CH, Yeh CH (2011), Treatment of Voiding Dysfunction in Neurogenic Bladder; Incont Pelvic Floor Dysfunct; 5(1):13-16 Amend B, Hennenlotter J, Schafer T et al (2008), Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High-Dosed Antimuscarinics without Increased Side-Effects European Urology;53: 1021–1028 10 Gulur, Drake (2010), Management of overactive bladder Review Urology; 7: 572–582 11 Lee CH, Yeh CH (2011), Treatment of Voiding Dysfunction in Neurogenic Bladder; Incont Pelvic Floor Dysfunct; 5(1):13-16 12 Del Popolo G, Mencarini M, Nelli F et al (2012), Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: A literature overview Spinal Cord; 50: 8–13 13 Kuo HC (2010), Intravesical Treatment for Overactive Bladder Refractory to Antimuscarinics Incontinence Pelvic Floor Dysfunction; 4(1): 5-9 14 Schurch B, de Seze M, Denys P et al (2005), Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174: 196-200 15 Smith CP, Gangitano DA , Munoz A et al (2008), Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury Neurochemistry International;52:1068–1075 16 Thavaseelan J (2007), Botulinum Toxin Treatment for Neurogenic Detrusor Overactivity Incont Pelvic Floor Dysfunct;1:1-3 17 Nguyễn Xuân Nghiên, Cao Minh Châu cộng (2002), Vật lý trị liệu, phục hồi chức NXB y học: tr 615 18 Kirshblum S (2005), Rehabilitation of Spinal Cord Injury Physical Medicine and Rehabilitation by Lippincott Williams &Wilkins; 2: 17151720 19 Sinha D (2004), Prevention of spinal cord injury in developing countrie; th Asian SpinL Cord Netk Conference in Kathmandu Nepal; 63 - 66 20 Gwynedd E Pickett, MD, FRCSC et al (2006), Epidemiology of Traumatic Spinal Cord Injury in Canada Spine Volume 31, Number 7: 799–805 21 Schoenfeld AJ, McCriskin B, Hsiao M, et al (2011), Incidence and epidemiology of spinal cord injury within a closed American population: the United States military (2000–2009); Spinal Cord, 49, pp 874–879 22 Vũ Thị Hiền Trinh, Cao Minh Châu (2005), Nghiên cứu dịch tễ học lâm sàng kết phục hồi chức cho bệnh nhân tổn thương tủy sống Trung tâm Phục hồi chức bệnh viện Bạch Mai Luận văn tốt nghiệp bác sỹ đa khoa, Đại học Y Hà Nội 23 De Groat WC, Yoshimura N (2012), Plasticity in reflex pathways to the lower urinary tract following spinal cord injury; Experimental Neurology; 235: 123–132 24 Michel MC, Oelkeb M, Peters S (2005), The Neuro-Urological Connection European Urology Supplements 4: 18–28 25 Abrams P and Karl-Erik A (2007), Muscarinic receptor antagonists for overactive bladder Journal compilation BJU International; 100: 9871006 26 Valentino RJ, Susan KW, Alan JW et al (2011), The bladder - brain connection: putative role of corticotrophin - releasing factor Urology; 8: 19–28 27 De Groat WC, Yoshimura N (2010), Changes in Afferent Activity After Spinal Cord Injury Neurourology Urodynamics; 29(1): 63–76 28 Fowler CJ, Griffiths D and de Groat WC (2008), The neural control of micturition Nat Rev Neurosci; 9(6): 453–466 29 Abrams P, Artibani W, Cardozo L et al (2005), Clinical manual of incontinence in women Health publication; 1: 6-15 30 Joseph G, Ouslander JG (2004), Management of Overactive Bladder The New England Journal of Medicine; 7: 786- 792 31 Birder LA and Groat WC (2007), Mechanisms of Disease: involvement of the urothelium in bladder dysfunction Nature clinical practice urology; vol.4; No.1: 1-4 32 Dorsher PT and Mc Intosh PM (2012), Review Article Neurogenic Bladder Advances in Urology Volume 2012; No.10: 1-16 33.Huang ST (2008), The Role of Antimuscarinics in the Treatment of Neurogenic Detrusor Overactivity in Patients with Stroke, Spinal Cord Injury and Parkinson's Disease Incont Pelvic Floor Dysfunct; (Suppl 1): 25-28 34 Linsenmeyer T, Maddox S, et al (2006), Bladder Management Following Spinal Cord Injury: What You Should Know A Guide for People with Spinal Cord Injury Spinal Cord Medicine;35: 1-36 35.Wyndaele J.J, Kovindha A, Igawa Y et al (2010), Neurologic Urinary and Faecal Incontinence; Neurourology and Urodynamics; 29: 207–212 36 Abrams P, Cardozo L, Fall M, et al (2002), The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Neurourology & Urodynamics; 21(2):167-78 37 Abrams P (2006), Urodynamics; Springer-Verlag London Limited:1-147 38 Blaivas J, Chancellor M, Weiss J et al (2007), Atlas of urodynamics; Lippincott Williams & Wilkins.1-239 39 GÜMÜŞ D, BAĞDATLI Y (2010), A bacteriological examination of urine before and after urodynamic testing Turk J Med Sci 40 (2): 317-322 40 Quek P, Tay LH (2004), Morbidity and Significant Bacteriuria after Urodynamic Studies Ann Acad Med Singapore; 33: 754-7 41 Taweel WA, Alkhayal A (2011), Neurogenic bladder evaluation and management after spinal cord injury: Current practice among urologists working in Saudi Arabia Urology Annual; 3(1): 24–28 42 Homma Y, Batista J, Bauer S et al (2010), Urodynamics (chap 07); Neurourology and Urodynamics; 317-372 43 Klausner AP, Steers WD (2011), The Neurogenic Bladder: An Update with Management Strategies for Primary Care Physicians Med Clin N Am 95: 111–120 44 Anne P and Cameron AP (2011), The role of ambulatory urodynamics in spinal cord injury National Review of Urology; 8: 298–299 45 Schafer W, Abrams P, Liao L et al (2002), Goodurodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies Neurourol Urodyn; 21:261–274 46 Stohrer M, Blok B, Castro-Diaz D et al (2009), EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction European Urology; 56: 81–88 47 Wyndaele J.J (2005), Practical Management of Neurogenic Bladder in the Spinal Cord Injured Patients Turk J Phys Med Rehab;51(Suppl B): B1-B7 48 Corcos J and Schurch B (2006), Use of Botulinum Toxin in Overactive Bladder European urology sup plements; 5: 667–669 49 Grosse J, Kramer G and Jakse G (2009), Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study BJU International; 104: 651– 656 50 Tow AM, Toh KL, Chan S-P et al (2007), Botulinum Toxin Type A for Refractory Neurogenic Detrusor Overactivity in Spinal Cord Injured Patients in Singapore Medicine Singapore; 36:11-7 51 Chapple CR (2012), β3-Agonist Therapy: A New Advance in the Management of Overactive Bladder? European Urology; 62: 841–842 52 Kanai A, Zabbarova I, Oefelein M et al (2012), Mechanisms of Action of Botulinum Neurotoxins, 3-Adrenergic Receptor Agonists, and PDE5 Inhibitors in Modulating Detrusor Function in Overactive Bladders Neurourology and Urodynamics 31:300–308 53 Wyndaele J.J, Brauner A, Geerlings SE et al (2012), Clean intermittent catheterization and urinary tract infection: review and guide for future research BJU Iternational; 110: E910–E917 54 Andersson K-E (2011), Antimuscarinic Mechanisms and the Overactive Detrusor: Review- Voiding Dysfunction European Urology; 59: 377–386 55 Reitz A, Stohrerb M , Kramer G, et al (2004), European Experience of 200 Cases Treated with Botulinum-A Toxin Injections into the DetrusorMuscle for Urinary Incontinence due to Neurogenic Detrusor Overactivity European Urology; 45: 510–515 56 Klaphajone J, Kitisomprayoonkul W, Sriplakit S (2005), Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions; Arch Phys Med Rehabil; 86: 2114-8 57 O’Leary M, Dierich M (2010), Botulinum Toxin Type A for the Treatment of Urinary Tract Dysfunction in Neurological Disorders Urologic Nursing; Volume 30, Number 4: 228-233 58 Ruffion A, Capelle O, Parapel P et al (2006), What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int; 97: 1030-4 59 Schurch B, Schulte-Baukloh H (2006), Botulinum Toxin in the Treatment of Neurogenic Bladder in Adults and Children European urology supplements 5: 679–684 60 Krebs J, and Pannek J (2013), Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion Spinal Cord; 51: 306–309 61 Visco AG, Brubaker L, Richter HE et al (2012), Anticholinergic Therapy vs OnabotulinumtoxinA for Urgency Urinary Incontinence N Engl J Med; 367:1803-13 62 Carruthers A, Carruthers J (2013), Botulinum toxin Elservier Saunders: 1-26 63 Truong D (2009), Manual of Botulinum toxin therapy Cambridge university Press, New York:1-23 64 Moore AP (1995), “Handbook of Botulinum Toxin Treatment”, Blackwell Science Ltd, Oxford 65 Patel AK, Patterson JM, Chapple CR (2006), Botulinum Toxin Injections for Neurogenic and Idiopathic Detrusor Overactivity: A Critical Analysis of Results European urology 50: 684–710 66 MacDonald R, Fink HA, Huckabay C (2007), Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects Review, Spinal Cord 45: 535–541 67 Hori S, Patki P, Attar KH et al (2009), Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury; BJU Internatinal; 104: 216–220 68 Gamé X, Castel-Lacanal E, Bentaleb Y et al (2008), Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections Eur Urol; 53:613–618 69 Novara G (2008), Botulinum toxin A detrusor injections inn patients with neurogenic detrusor overactivity singificantly decrease the incidence of symptomatic urinary tract infection European Urology 53: 618-619 70 Abdel-Meguid TA (2010), Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder - To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial The Journal of Urology; Vol 184, 2423-2428 71 Wefer B, Ehlken B, Bremer J et al (2010), Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany World J Urol; 28: 385–390 72 Kulaksizolu (2010), Botulinum Toxin Applications in Overactive Bladder Symptoms Secondary to Neurological Diseases; Archives of Neuropsychiatry; 47 Supplement: 44-7 73.Herschorn S, Gajewski J, Ethans K et al (2011), Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial JUrol; 185: 2229–2235 74 Schulte-Baukloh H (2012), Botulinum toxin for neurogenic bladder dysfunction; Urologe; 51:198–203 75 Del Popolo G (2008), Botulinum Toxin A Era: Little Steps Towards a Better Understanding European Urology 54: 25–27 76 Médée B, RuffionA (2009), Intérêt et résultats de l’utilisation de la toxine botulique dans l’hyperactivité détrusorienne d’origine neurologique Pelv Perineol; 4: 60-66 77 Nitti V.W (2006), Botulinum Toxin for the Treatment of Idiopathic and Neurogenic Overactive Bladder: State of the Art Reviews in urology, vol 8; No 4: 198-206 78 Rapp DE, Lucioni A, Bales GT (2007), Botulinum toxin injection: a review of injection principles and protocols Int Braz J Urol; 33(2):132– 141 79 Ehren I, Volz D, Farrelly E et al (2007), Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study Scandinavian Journal of Urology and Nephrology; 41: 335-340 80 Kennelly M, Dmochowski R, Ethans K et al (2013), Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis Urology; 81: 491- 497 81 Curcio L, Costa F, Marinho MA et al (2008), Use of Botulinum Toxin Type A (Botox®) Through Transcystoscopic Vesical Insertion for Overactive Bladder Syndrome Non-Responsive to Oral Medication or for Parasympatholytic Drugs use Severe Side Effects Braz J Video-Sur, v 1, n 3: 097-103 82 Chuang YC, Kuo H-C and Chancellor MB (2010), Botulinum toxin for the lower urinary tract; review article; BJU International; 105: 1046 – 1058 83 Chen C-Y, Liao C-H, Kuo H-C et al (2011), Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia Spinal Cord; 49: 659–664 84 Del Popolo G , Filocamo MT, Marzi VL et al (2008), Neurogenic Detrusor Overactivity Treated with English Botulinum Toxin A: 8-Year Experience of One Single Centre European Urology; 53: 1013–1020 85 Kalsi V, Apostolidis A, Gonzales G et al (2008), Early Effect on the Overactive Bladder Symptoms following Botulinum Neurotoxin Type A Injections for Detrusor Overactivity European Urology; 54: 181–187 86 MacDiarmid S, Anderson RU, Armstrong RB et al (2005), Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from flexible dosing studies The Journal of urology; vol. 174 (1), no4,1301-1305(P1=0,46%) 87 Hubsher CP and Costa J (2009), Urologic Management of a Patient with Neuropathic Voiding Dysfunction Northeast Florida Medicine Vol 60, No 3: 13-17 88 Bothig R, Fiebag K, Thietje R et al (2013), Morbidity of urinary tract infection after urodynamic examination of hospitalized SCI patients: the impact of bladder management Spinal Cord; 51, 70–74 89 Pannek J, Nehiba M et al (2007), Morbidity of urodynamic testing in patients with spinal cord injury: is antibiotic prophylaxis necessary? Spinal Cord; 45: 771–774 90 Krhut J, Samal V, Nemec D et al (2012), Intradetrusor versus suburothelial onabotulinumtoxin A injections for neurogenic detrusor overactivity: a pilot study Spinal Cord; 50: 904–907 91 Okamura K, Nojiri Y, Ameda K et al (2011), Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: Early outcomes International Journal of Urology 18: 483–487 92 Jeffery S, Fynes M, Lee F et al (2007), Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity BJU International; (100): 1302–1306 93 Kirshblum SC, Burns SP, Biering-Sorensen F, et al (2011), International standards for neurological classification of spinal cord injury; J Spinal Cord Med;34(6):535–46 94.Apostolidis A, Popat R, Harper M et al (2007), Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty Nature Clinical Practice Urology; (5): 280-284 95 Chen G, Liao L (2011), Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury; Int Urol Nephrol; 43:655–662 96 Gray M (2011), Traces: Making Sense of Urodynamics Testing – Part 4: Preparing the Patient for Multichannel Urodynamics Testing Urologic Nursing; Volume 31 Number 2: 71-77 97 Gray M (2012), Traces: Making Sense of Urodynamics Testing – Part 9: Evaluation of Detrusor Response To Bladder Filling Urologic Nursing; Volume 32 Number 1: 21-28 98 Khanna CR, Sandhu CAS, Doddamani CD (2009), Urodynamic management of Neurogenic Bladder in Spinal Cord Injury MJAFI, Vol 65: 300-304 99 Suzuki Bellucci CH, Wöllner J, Gregorini F et al (2012), Neurogenic Lower Urinary Tract Dysfunction—Do We Need Same Session Repeat Urodynamic Investigations? The Journal of Urology; Vol 187, 13181323 100 Jia C, Liao L-M, Chen G et al (2013), Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury Spinal Cord; 51: 487–490 101 Akkoca Y, Cinar Y and Kismali E (2012), Should complete and incomplete spinal cord injury patients receive the same attention in urodynamic evaluations and ultrasonography examinations of the upper urinary tract? International Journal of Rehabilitation Research, Vol 35 No 2: 178-180 102 Ginsberg D, Gousse A, Keppenne V et al (2012), Phase Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity The journal of urology; Vol 187: 2131-2139 103 Đỗ Đào Vũ, Cao Minh Châu (2006), Bước đầu đánh giá hiệu phục hồi chức cho bệnh nhân liệt tứ chi sau chấn thương cột sống cổ Luận văn tốt nghiệp bác sỹ nội trú, Đại học Y Hà Nội 104 Cầm Bá Thức, Nguyễn Xuân Nghiên, Cao Minh Châu (2008), Nghiên cứu thực trạng bệnh nhân liệt hai chi chấn thương tủy sống cộng đồng đề xuất số giải pháp can thiệp Luận văn tốt nghiệp tiến sỹ y khoa, Đại học Y Hà Nội 105 Lombardi G, Celso M, Mencarini M et al (2013), Clinical efficacy of intravesical electrostimulation on incomplete spinal cord patients suffering from chronic neurogenic non-obstructive retention: a 15-year single centre retrospective study Spinal Cord; 51: 232–237 106 Furusawa K, Tokuhiro A, Sugiyama H et al (2011), Incidence of symptomatic autonomic dysreflexia varies according to the bowel and bladder management techniques in patients with spinal cord injury Spinal Cord; 49: 49–54 107 Nosseir M, Hinkel A, and Pannek J (2007), Clinical Usefulness of Urodynamic Assessment for Maintenance of Bladder Function in PatientsWith Spinal Cord Injury Neurourology and Urodynamics 26: 228-233 108 Luo D-Y, Ding M-F, He C-Q et al (2012), Bladder management of patients with spinal cord injuries sustained in the 2008 Wenchuan earthquake Kaohsiung Journal of Medical Sciences; 28: 613-618 109 Birzele J, Mehnert U, Reuter K et al (2009), Preserving voiding function and alleviation of Overactive Bladder symptoms with 100 units of Botulnum neurotoxin A, In multiple Sclerosis patients: a Promising therapy? Eur Urol Suppl;8(4):242 110 Conté A, Giannantoni A, Proietti S, et al (2012), Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity European Journal of Neurology, 19: 725–732 111 Stohrer M, Murtz G, Kramer G et al (2007), Propiverine Compared to Oxybutynin in Neurogenic Detrusor Overactivity – Results of a Randomized, Double-blind, Multicenter Clinical Study European Urology; 5: 235–242 112 Kessler TM, Khan S, Panicker J et al (2009), Clean Intermittent SelfCatheterization After Botulinum Neurotoxin Type A Injections ShortTerm Effect on Quality of Life Obstet Gynecol;113:1046–51 113 Michel MC, Chapple CR (2009), Basic Mechanisms of Urgency: Preclinical and Clinical Evidence European Urology; 56: 298–308 114 Chen S-L, Bih L-I, Huang Y-H et al (2008), Effect of single Botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury Journal of Rehabilitation Medicine; 40: 744–748 115 Gamé X, Chartier-Kastler E, Ayoub N et al (2008), Outcome after treatment of detrusor–sphincter dyssynergia by temporary stent Spinal Cord 46: 74–77 116 Rickey LM, Kenton K (2008), Botulinum Toxin: New Option for Refractory Lower Urinary Tract Symptoms in Women Clinical Obstetrics and Gynecology; Volume 51, Number 1, 176–186 117 Bersch U, Gocking K, Pannek J (2009), The Artificial Urinary Sphincter in Patients with Spinal Cord Lesion: Descriptionof Modified Technique and Clinical Results European Urology 55: 687–695 118 Schulte-Baukloha H, Weißa C, Stolzea T et al (2005), BotulinumAToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction European Urology; 48: 984–990 119 Safari S, Jamali S, Habibollahi P et al (2010), Intravesical Injections of Botulinum Toxin Type A for Management of Neuropathic Bladder: A Comparison of Two Methods Urology; 76: 225–232 120 Gallien P, Durufle A, Nicolas B et al (2009), Indication et résultats de la toxine botulique en injection intrasphinctérienne dans les dysuries d’origine neurologique Pelv Perineol 4: 67-71 121 Đỗ Đào Vũ, Lương Tuấn Khanh, Cao Minh Châu (2013), Rối loạn phản xạ tự động tủy thăm dò niệu động học bệnh nhân tổn thương tủy sống.Tạp chí y học thực hành Bệnh viện Bạch Mai; số 74 Tr 53-60 122 Li X, Song B, Su Y et al (2012), High bladder pressure during urine storage is a main reason of upper urinary tract damage by voiding dysfunction diseases Pak J Med Sci July – September; Vol 28 No 716-721 123 Yokoyama T, Chancellor MB, Oguma K et al (2012), Botulinum toxin type A for the treatment of lower urinary tract disorders International Journal of Urology; 19: 202–215 124 Alloussi S.H, Lang Ch, Eichel R et al (2012), Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment World J Urol; 30:367–373 125 Karsenty G, Denys P, Amarenco G, et al (2008), Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review Eur Urol; 53(2): 275–287 126 Cruz F, Herschorn S, Aliotta P et al (2011), Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebocontrolled trial Eur Urol; 60: 742–750 127 Elkelini MS, Bagli DJ, Fehlings M et al (2011), Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor BJU International; 109: 402–407 128 Watanabe M, Yamanishi T, Honda M et al (2010), Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder International Journal of Urology; 17: 931–936 129 Fowier CJ (2011), Systematic review of therapy for neurogenic detrusor overactivity Therapy for neurogenic detrusor overactivity; Can Urol Assoc ;5(Suppl 2): S146-S148 130 Jeong SJ, Lee SC, Jeong CW et al (2013), Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity Int Urogynecol J 24:255–261 131 Schurch B, Denys P, Kozma CM et al (2007), Reliability and validity of the incontinece quality of life questionnaire in Patients with Neurogenic Urinary Incontinence Arch phys med rehabil; vol 88: 646652 132 De Leaf K, Wyndaele J-J (2005), Adverse events after botulinum A toxin injection for neurogenic voiding disorders Spinal Cord; 43: 397-9
Ngày đăng: 02/07/2023, 08:51
Xem thêm:
